STOCK TITAN

Neximmune Inc - NEXI STOCK NEWS

Welcome to our dedicated news page for Neximmune (Ticker: NEXI), a resource for investors and traders seeking the latest updates and insights on Neximmune.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neximmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neximmune's position in the market.

Rhea-AI Summary
NexImmune, Inc. has announced the closing of a registered direct offering of 304,731 shares of its common stock at a purchase price of $12.05 per share, resulting in gross proceeds of approximately $3.67 million. The company intends to use the net proceeds for additional financing, potential business development and collaboration opportunities, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.46%
Tags
offering
-
Rhea-AI Summary
NexImmune, Inc. announced a definitive agreement for the issuance and sale of 304,731 shares of common stock at a purchase price of $12.05 per share in a registered direct offering. The company also agreed to issue unregistered warrants to purchase up to an aggregate of 304,731 shares of its common stock. The closing of the offering is expected to occur on or before February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
offering
-
Rhea-AI Summary
NexImmune extends research partnership with Yale and JDRF to explore the use of antigen-specific nanoparticles and anti-CD3 mAb for type 1 diabetes treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
partnership
Rhea-AI Summary
NexImmune announces acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
-
Rhea-AI Summary
NexImmune announces approval of 1-for-25 reverse stock split to increase per share trading price and regain compliance with Nasdaq listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1924.89%
Tags
none
-
Rhea-AI Summary
NexImmune, Inc. reduces workforce by 53% to cut costs and extend cash
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
earnings
Neximmune Inc

Nasdaq:NEXI

NEXI Rankings

NEXI Stock Data

10.13M
753.16k
22.4%
7.72%
13.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Gaithersburg

About NEXI

neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.